#drug approval

[ follow ]
#drug-approval
english.elpais.com
3 days ago
OMG science

A scientific rebellion to get Europe to approve a controversial Alzheimer's drug

Lecanemab represents a breakthrough for Alzheimer's treatment but faces significant controversy regarding its efficacy, safety, and accessibility. [ more ]
New York Post
3 days ago
Media industry

Ex-NYC COVID czar details in secret recording how to use media to 'spin' monkeypox drug stories

Dr. Jay Varma's comments suggest manipulative media tactics were utilized to gain FDA approval for a drug with questionable efficacy. [ more ]
Nature
2 weeks ago
Medicine

Europe sidelines Alzheimer's drug: lessons must be learnt

The EMA's cautious approach may deny patients access to effective Alzheimer's treatment, contrasting with global acceptances of lecanemab. [ more ]
www.bbc.com
1 month ago
OMG science

First drug to slow Alzheimer's too costly for NHS

NICE has decided against funding lecanemab on the NHS, citing insufficient benefits relative to the treatment costs. [ more ]
Inverse
1 month ago
Medicine

The Future of Psychedelic Research Is In Limbo - Why the FDA's Decision Changed Everything

The FDA declined Lykos Therapeutics' MDMA-assisted therapy application, signaling challenges for psychedelic drug approval. [ more ]
www.nytimes.com
7 months ago
Medicine

Biogen Abandons Its Controversial Alzheimer's Drug Aduhelm

Biogen is abandoning its ownership rights to the Alzheimer's drug Aduhelm, after it failed to gain traction in the market.
The decision to abandon Aduhelm comes after the drug faced criticism for its weak evidence of efficacy, high price, and safety risks. [ more ]
english.elpais.com
3 days ago
OMG science

A scientific rebellion to get Europe to approve a controversial Alzheimer's drug

Lecanemab represents a breakthrough for Alzheimer's treatment but faces significant controversy regarding its efficacy, safety, and accessibility. [ more ]
New York Post
3 days ago
Media industry

Ex-NYC COVID czar details in secret recording how to use media to 'spin' monkeypox drug stories

Dr. Jay Varma's comments suggest manipulative media tactics were utilized to gain FDA approval for a drug with questionable efficacy. [ more ]
Nature
2 weeks ago
Medicine

Europe sidelines Alzheimer's drug: lessons must be learnt

The EMA's cautious approach may deny patients access to effective Alzheimer's treatment, contrasting with global acceptances of lecanemab. [ more ]
www.bbc.com
1 month ago
OMG science

First drug to slow Alzheimer's too costly for NHS

NICE has decided against funding lecanemab on the NHS, citing insufficient benefits relative to the treatment costs. [ more ]
Inverse
1 month ago
Medicine

The Future of Psychedelic Research Is In Limbo - Why the FDA's Decision Changed Everything

The FDA declined Lykos Therapeutics' MDMA-assisted therapy application, signaling challenges for psychedelic drug approval. [ more ]
www.nytimes.com
7 months ago
Medicine

Biogen Abandons Its Controversial Alzheimer's Drug Aduhelm

Biogen is abandoning its ownership rights to the Alzheimer's drug Aduhelm, after it failed to gain traction in the market.
The decision to abandon Aduhelm comes after the drug faced criticism for its weak evidence of efficacy, high price, and safety risks. [ more ]
moredrug-approval
#gene editing
www.fastcompany.com
10 months ago
Health

The U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to follow

U.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia.
The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year.
The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level. [ more ]
www.fastcompany.com
10 months ago
Health

The U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to follow

U.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia.
The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year.
The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level. [ more ]
www.fastcompany.com
10 months ago
Health

The U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to follow

U.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia.
The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year.
The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level. [ more ]
www.fastcompany.com
10 months ago
Health

The U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to follow

U.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia.
The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year.
The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level. [ more ]
moregene editing
[ Load more ]